Opinion & analysis

Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting

Is a suffix that distinguishes biosimilars and other biologic products necessary in adverse event reporting? The US FDA says yes, although to date, nearly every adverse event report received by the FDA have identified biosimilars simply by their brand names.

Get a more in-depth analysis on Pharmaceutical market trends with our Opinion on Analysis reports.

Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting

Telehealth, Wearables and Apps – Report 3

OTC Distribution in Europe – The New Global Agenda

FDA’s Quality System Regulation Is Mapped To International Standard ISO 13485 – And Vice Versa – In New Report From AAMI

The Emergence Of IO

Herbalife Shakes Up Executive Suite Due To CEO’s Earlier Statements On Expenses

AHPA Backs NDI Filing For Kratom, Experts Question FDA Enforcement

Missed Opportunities: 10 Questions We Wish Senators Had Asked At The Drug Pricing Hearing

Commission Looks Set To Expand MDR Extension So Notified Bodies Can Focus On High-Risk Devices

Bayer’s US Playbook: The Smart Way To Top-Line Growth

2018 Completed Clinical Trials: Change Is The New Constant

Novartis’ Zolgensma Had Manipulated Data In Application, US FDA Says

Real-World Evidence Takes Courage: A Conversation With IQVIA’s Nancy Dreyer

The Next New Thing In FDA Inspections: Poor Root Cause Investigations

Contamination In Common OTC Antacid Adds To FDA’s API Impurity Concerns

FDA Asks Whether Supplement Industry Has Outgrown Regulatory Framework

Special Report: The Intersection Between Tech and Pharma (Part 1. Google)

Nitrosamine Episode Could Lead To Paradigm Shift In Quality

Biogen CMO Notes iPhone’s Potential For Early Detection of Alzheimer’s

What’s Under The Iceberg: GE Healthcare’s Deep Dive Look At Future Of Gene Therapy

Sanofi Prioritizes Cancer And Rare Diseases In Pipeline Shake-Up

BSI Is Designated In Netherlands, Giving Clients Go-Ahead To Start Transfer Of Certificates

Engaging Patients and Navigating Laws: What To Consider When Developing Health Apps

Two More EU Notified Bodies But Not On Nando Yet

Patients’ Preferred Endpoints May Not Satisfy Regulatory Needs, US FDA Says

Virtual AI Nurses And The Future Of Chronic Disease Management

Bristol-Myers, Celgene and The Perils Of The US Drug Pricing Environment

An FDA Age-Based Predicate Policy Would Be Arbitrary, Reg Experts Complain

Abbott Launches New App To Keep Heart Failure Patients Out Of The Hospital

FDA Ban On Flavoring Ingredients Should Prompt Removal From Fragrances – WVE